EW stock forecast, quote, news & analysis
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease... Show more
Edwards Lifesciences (EW) Stock Analysis: Navigating TAVR Leadership and Upcoming Q2 Earnings
Key Takeaways
- Edwards Lifesciences shares recently traded near $85, pulling back from early-July highs around $96 as investors await the company's Q2 2026 earnings release on July 23.
- Wall Street maintains a Moderate Buy consensus with an average price target of approximately $99, reflecting confidence in Edwards' dominant transcatheter aortic valve replacement (TAVR) franchise.
- Competitive dynamics in the TAVR market are shifting, with Medtronic facing headwinds that analysts estimate could translate to a 15–20% market share opportunity for Edwards.
- The company's Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is projected to grow 35–45% in 2026, driven by the PASCAL, EVOQUE, and SAPIEN M3 platforms.
- Key upcoming catalysts include the Q2 earnings report, updated U.S. TAVR guidelines expected by Q4 2026, and the PROGRESS trial readout at TCT 2026.
Current Market Snapshot
Edwards Lifesciences Corporation (NYSE: EW) has experienced a moderate pullback in recent weeks, with shares declining from a 52-week high of $96.29 reached in early July 2026 to the mid-$85 range by mid-July. The stock currently trades below its 50-day simple moving average of roughly $87, though it remains above its 200-day moving average near $84. With a market capitalization of approximately $49 billion and a price-to-earnings ratio around 46, Edwards commands a premium valuation reflective of its leadership position in the structural heart device market. Institutional investors hold roughly 79% of outstanding shares, underscoring broad confidence in the company's long-term growth trajectory.
Edwards Lifesciences (EW) Business Overview and Competitive Position
Edwards Lifesciences is the leading global structural heart innovation company, specializing in prosthetic heart valves and hemodynamic monitoring systems. The company's flagship SAPIEN platform dominates the transcatheter aortic valve replacement (TAVR) market, offering a minimally invasive alternative to open-heart surgery for patients with aortic stenosis. With over 1.2 million patients treated worldwide and more than 15 years of clinical trial data, SAPIEN remains the most studied and widely adopted TAVR system globally. Beyond TAVR, Edwards has built a growing Transcatheter Mitral and Tricuspid Therapies (TMTT) portfolio featuring the PASCAL, EVOQUE, and SAPIEN M3 systems, alongside a surgical valve business anchored by its RESILIA tissue technology. The company generates roughly 58% of revenue in the United States, with the remainder split across Europe, Japan, and other international markets. Edwards' competitive moat rests on decades of clinical evidence, deep relationships with interventional cardiologists and cardiac surgeons, and a focused R&D pipeline targeting underpenetrated indications such as asymptomatic aortic stenosis, tricuspid regurgitation, and structural heart failure.
Recent Developments Driving EW
Several converging factors have shaped Edwards Lifesciences' stock narrative over the past month. On the competitive front, challenges at Medtronic (MDT) in the TAVR space have created what multiple analysts describe as a significant market share opportunity for Edwards. Feedback from high-volume medical centers suggests Medtronic could lose 15–20% of its TAVR market share, a dynamic reminiscent of the share gains Edwards captured when Boston Scientific (BSX) previously exited the market. This competitive tailwind prompted several analyst price target increases, including Mizuho raising its target to $105, Citigroup and BTIG each moving to $110, and RBC Capital lifting to $110, all maintaining Buy-equivalent ratings.
On the regulatory front, Edwards and Genesis MedTech agreed to pay a combined $12 million penalty to settle Federal Trade Commission allegations related to the structuring of Edwards' 2024 acquisition of JC Medical. While financially immaterial, the settlement imposes ongoing FTC oversight and a mandated antitrust compliance program that investors are monitoring. On the clinical side, the company advanced its KONECTION real-world study for the KONECT RESILIA Aortic Valved Conduit, with patient recruitment actively underway as of mid-July. Edwards also announced its Q2 2026 earnings conference call for July 23, placing near-term investor focus squarely on updated financial results and forward guidance. The Q1 report in April impressed Wall Street with EPS of $0.78 on revenue of $1.65 billion, beating consensus estimates and reflecting 16.7% year-over-year revenue growth.
Trending AI Robots
For traders seeking a data-driven edge in navigating stocks like Edwards Lifesciences, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading robots that actively trade thousands of tickers across diverse strategies, timeframes, and risk profiles. The Trending AI Robots section highlights only those bots demonstrating the strongest recent performance and highest relevance in current market conditions, making it easier for users to identify potentially actionable trading ideas without sifting through the entire bot marketplace. Bots vary by strategy type—from swing trading to trend following—and differ in holding periods, win rates, and risk-adjusted return metrics. Exploring the page can help traders discover automated approaches aligned with their individual goals.
2026 Outlook and What Investors Should Watch
Looking ahead, Edwards Lifesciences' 2026 story hinges on several key catalysts. The July 23 Q2 earnings report will provide the first official update on whether the company remains on track to achieve its full-year guidance of 8–10% constant currency sales growth and adjusted EPS of $2.80–$2.95. The TMTT segment, guided to grow 35–45%, is a particular area of focus as the SAPIEN M3 transcatheter mitral valve replacement system advances toward anticipated FDA approval. Later in 2026, updated U.S. TAVR guidelines and a revised National Coverage Determination expected by Q4 could broaden the addressable patient population, while the PROGRESS trial readout at TCT 2026 may support TAVR expansion into moderate aortic stenosis patients. Investors should also monitor the evolving competitive landscape, Medtronic's response to its TAVR challenges, progress on the TRIFORMIS surgical valve launch, and any developments in Edwards' emerging structural heart failure initiative. Macroeconomic factors including hospital capital spending trends, tariff exposure, and currency fluctuations represent additional variables worth tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EW in upward trend: price may jump up because it broke its lower Bollinger Band on July 17, 2026
EW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where EW's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EW's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where EW's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EW advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 232 cases where EW Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EW as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EW turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
EW moved below its 50-day moving average on July 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EW crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EW declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EW’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.782) is normal, around the industry mean (11.000). P/E Ratio (51.048) is within average values for comparable stocks, (63.941). Projected Growth (PEG Ratio) (2.064) is also within normal values, averaging (4.027). EW has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (7.657) is also within normal values, averaging (29.285).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of products to treat late-stage cardiovascular disease
Industry MedicalNursingServices